Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Rachel Gillespie

Physician Assistant Harrisonburg, VA Physician Assistant

NPI 1174892400 CMS profile 11229663

563 Neff Ave Ste A, Harrisonburg, VA 22801

Open in the dashboard

General payments

$36,678

400 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rachel Gillespie of Harrisonburg, VA is reported in the CMS Open Payments database as having received $36,678 across 400 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26,374 145
2024 General $7,655 129
2023 General $2,101 92
2022 General $491 31
2021 General $56 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rachel Gillespie
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Rachel Gillespie were reported at $26,374. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Rachel Gillespie Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $56 $132 $37–$438 $132
2022 $491 $155 $48–$522 $149
2023 $2,101 $167 $52–$557 $160
2024 $7,655 $178 $55–$600 $164
2025 $26,374 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $30,182 121 payments
  2. AbbVie, Inc. $1,805 81 payments
  3. Regeneron Healthcare Solutions, Inc. $716 23 payments
  4. Sun Pharmaceutical Industries Inc. $692 33 payments
  5. E.R. Squibb & Sons, L.L.C. $661 21 payments
  6. UCB, Inc. $646 31 payments
  7. Novartis Pharmaceuticals Corporation $607 30 payments
  8. Incyte Corporation $359 14 payments
  9. Lilly USA, LLC $278 14 payments
  10. Genzyme Corporation $245 10 payments
  11. Other $486 22 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $25,538 15 payments
  2. Food and Beverage $8,041 368 payments
  3. Travel and Lodging $2,218 7 payments
  4. Education $881 10 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $30,182 121 payments
  2. SKYRIZI Immunology $1,143 53 payments
  3. SOTYKTU $646 20 payments
  4. Bimzelx $608 29 payments
  5. SKYRIZI Immunology $494 16 payments
  6. DUPIXENT Inflammation And Immunology $440 14 payments
  7. DUPIXENT Immunology $413 17 payments
  8. COSENTYX $370 19 payments
  9. OPZELURA $359 14 payments
  10. ILUMYA $307 25 payments
  11. Other $1,639 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

784

Median for Physician Assistant: 241

Drug cost

$365,743

Median for Physician Assistant: $4,110

Branded share of claims

10.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 26 $185,970
Dupixent Pen Dupilumab Brand 24 $111,320
Dupixent Syringe Dupilumab Brand 13 $49,392
Clobetasol Propionate Generic 106 $5,867
Fluorouracil Generic 42 $3,471
Ketoconazole Generic 185 $2,844
Triamcinolone Acetonide Generic 218 $2,009
Metronidazole Generic 41 $1,990
Doxycycline Hyclate Generic 44 $1,644
Clindamycin Phosphate Generic 18 $630

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$167,425

Of which drugs: $2,869

Medicare patients

1,376

Average age 75

Services billed

5,914

763 women, 613 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 42%
Diabetes 25%
Ischemic heart disease 18%
Chronic kidney disease 18%
Depression 16%
Atrial fibrillation 14%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $5,387
$5,387 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $427
  • GENZYME CORPORATION $62
$489 37 —
SKYRIZI
  • AbbVie, Inc. $458
$458 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $438
$438 — —
Bimzelx
  • UCB, Inc. $215
$215 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

400 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record